# EDGAR Filing Document

**Accession Number:** 0001840229
**File Stem:** 0001193125-25-221863
**Filing Date:** 2025-9
**Character Count:** 11247
**Document Hash:** 8fee7266cc8e37f5cf647a29d5e22512
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-221863.hdr.sgml**: 20250929

**ACCESSION NUMBER**: 0001193125-25-221863

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20250923

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250929

**DATE AS OF CHANGE**: 20250929

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MiNK Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001840229
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40908
- **FILM NUMBER:** 251352552

**BUSINESS ADDRESS:**
- **STREET 1:** 149 FIFTH AVENUE
- **STREET 2:** SUITE 500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** 212-994-8250

**MAIL ADDRESS:**
- **STREET 1:** 149 FIFTH AVENUE
- **STREET 2:** SUITE 500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AgenTus Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20210112

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** September 23, 2025<br>

------

MiNK Therapeutics, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-40908 | 82-2142067 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 149 Fifth Avenue<br>Suite 500 |  |  |
| New York**,** New York |  | 10010 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 212 994-8250<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, par value $0.00001 per share | INKT | The Nasdaq Stock Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 23, 2025, the Board of Directors (the "Board") of MiNK Therapeutics, Inc., ("MiNK") elected Dr. John Holcomb to become a Class II director of MiNK with an initial term that expires at MiNK's annual meeting of stockholders in 2026.

In connection with his election to the Board, Dr. Holcomb was granted an option to purchase 4,174 shares of MiNK's common stock pursuant to MiNK's 2021 Equity Incentive Plan and MiNK's non-employee director compensation program. The option has a per-share exercise price equal to the closing price of MiNK's common stock on the Nasdaq Capital Market on the date of grant and a 10-year term, and it vests over three years in equal annual installments (provided Dr. Holcomb maintains a service relationship with MiNK through each such vesting date). As a non-employee director, Dr. Holcomb will also receive cash and possible additional equity compensation paid by MiNK pursuant to its non-employee director compensation program. There are no arrangements or understandings between Dr. Holcomb and any other person pursuant to which Dr. Holcomb was selected as a director, and there are no transactions between Dr. Holcomb and MiNK that would require disclosure under Item 404(a) of Regulation S-K.

On September 29, 2025, MiNK issued a press release announcing Dr. Holcomb's appointment to the Board. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

## Item 9.01 Financial Statements and Exhibits.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1 [<u>Press Release dated September 29, 2025</u>](inkt-ex99_1.htm)

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date: | September 29, 2025 | By:  | /s/ Jennifer S. Buell, Ph.D. |
|  |  |  | Jennifer S. Buell, Ph.D., CEO |

---

------

## Exhibit 99.1

**Exhibit 99.1**

**MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*Strengthening Leadership to Accelerate iNKT Therapies into Immune-Mediated Disease, Pulmonary Disorders, and Global Health Security*

New York, NY *–* September 29, 2025 – MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced the appointment of Colonel (Ret.) John B. Holcomb, MD, FACS to its Board of Directors.

Dr. Holcomb is a globally recognized authority in trauma and critical care, having served 23 years in the U.S. Army, including as Commander of the U.S. Army Institute of Surgical Research and Trauma Consultant to the Army Surgeon General. He pioneered major innovations in combat casualty care, transfusion medicine, and trauma systems design that saved countless lives and reshaped global health protocols. Post-military, he has continued to drive impact in academic medicine and biotech, with more than 780 peer-reviewed publications, multiple board memberships, and leadership in prehospital blood transfusion programs.

Dr. Holcomb's appointment comes at a time when Americans face escalating challenges from cancer, rising rates of pulmonary disease, multidrug-resistant infections, and the persistent threat of emerging pandemics. He joins MiNK alongside recently appointed pulmonary critical care expert Dr. Terese Hammond, reinforcing MiNK's commitment to tackling diseases of profound epidemiologic burden where both patient lives and public health security are at stake.

"We are honored to welcome Dr. Holcomb to the MiNK Board at this transformative stage in our company's journey," said Dr. Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics. "John's unmatched expertise in trauma and surgical critical care medicine, immune activation, and clinical trial execution brings MiNK precisely the kind of insight needed as we advance iNKT cell therapies into late-stage development. His deep experience in building systems of care — from the battlefield to the ICU — and his leadership across global health networks will help us design and deliver programs that address the most pressing challenges. John's perspective will be instrumental in guiding MiNK toward its next phase of growth, preparedness, and impact."

"MiNK is advancing iNKT cell therapies with the potential to change how we treat interrelated immune-driven diseases seen on the battlefield and in our acute care hospitals — from trauma and ARDS to multi drug-resistant infections. This unique cellular therapy offers a new approach where current therapies have fallen short, addressing conditions that share common pathways of immune dysregulation. I am eager to help guide MiNK as it brings these breakthroughs closer to patients and strengthens our national preparedness for impending health crises," said Dr Holcomb.

Dr. Holcomb's appointment reinforces MiNK's commitment to clinical rigor and operational excellence as the company continues to scale its therapeutic pipeline and global footprint.

------

**About MiNK Therapeutics**

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK's proprietary platform is designed to restore immune balance and drive cytotoxic immune responses across cancer, immune-mediated diseases, and pulmonary immune failure. MiNK's lead asset, AGENT-797, is an off-the-shelf, allogeneic iNKT cell therapy currently in clinical development for the treatment of graft-versus-host disease (GvHD), solid tumors, and critical pulmonary immune collapse. MiNK is also advancing a pipeline of T cell receptor (TCR)-based therapies and neoantigen discovery tools that enable tumor- and tissue-specific immune activation with broad potential application. With a scalable, cryopreserved manufacturing process and a differentiated mechanism that bridges innate and adaptive immunity, MiNK is committed to developing next-generation immune reconstitution therapies that are accessible, durable, and applicable across a wide range of indications. For more information, visit https://minktherapeutics.com or follow us on X @MiNK_iNKT.

**Forward-Looking Statements**

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, safety, anticipated benefit, development plans, and future potential of iNKT cells and CAR-iNKT therapies. These forward-looking statements are subject to risks and uncertainties, including those described under the "Risk Factors" section of MiNK's most recent filings with the Securities and Exchange Commission. MiNK cautions investors not to place undue reliance on these statements. The company undertakes no obligation to update or revise any forward-looking statements, except as required by law.

Investor Contact

917-362-1370

investor@minktherapeutics.com

Media Contact

781-674-4428

communications@minktherapeutics.com

------